FORT MYERS, Fla. — A best practices program developed at Florida Cancer Specialists & Research Institute (FCS) has been shown to improve outcomes for adult patients prescribed selinexor for the treatment of relapsed/refractory multiple myeloma (RRMM). Results obtained from a one-year retrospective observational study using data collected by FCS’ Real-World...
research News
Fuzhou, China – Flow immunophenotyping can help diagnose primary myelofibrosis (MF) and differentiate between essential thrombocythemia (ET) and polycythemia vera (PV), according to a new study published in the journal Clinical Cytometry. It is difficult to differentiate between the different types of myeloproliferative neoplasms (MPNs), such as ET, PV, and...
CARY, N.C. — Focal Medical, Inc., a privately held biopharmaceutical company developing a targeted therapeutic system to treat inoperable tumors and to deliver genomic medicines, today announced U.S. Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application to initiate a Phase 1b clinical trial of ACT-IOP-003,...
Patients in a Phase 3 clinical trial who received sotorasib and panitumumab lived longer, suggesting the combination therapy could become the new standard of care, according to a new City of Hope study. LOS ANGELES, Calif. — A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic...
Eliminating animal milk alone from the diet of adults with eosinophilic esophagitis, or EoE, is as effective at treating the disease as eliminating animal milk plus five other common foods, a clinical trial has found. For people with EoE whose disease remains active after they forgo animal milk, a more restrictive diet may help them achieve remission, according to the researchers.
Philadelphia, PA – FORTE (NRG-CC005) is a highly anticipated colorectal cancer prevention trial led by NRG Oncology examining surveillance colonoscopy intervals in participants who have non-advanced polyps. Expected to enroll 9,500 participants (about 4,750 people in each study group), we are excited to announce that FORTE accrued its 1000th participant...
Eureka! Vancouver scientists from the Ovarian Cancer Research (OvCaRe) Program at BC Cancer Agency and Vancouver Coastal Health Research Institute have discovered that there appears to be a single spelling mistake in the genetic code of granulosa cell tumours, a rare and often untreatable form of ovarian cancer. This means...
AUSTIN, Texas and NEW YORK, NY — The Foundation for Angelman Syndrome Therapeutics (FAST), the leading patient advocacy organization working to support the development of transformative treatment options for Angelman syndrome, today announced that it has entered into an agreement with Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for...
CHICAGO, Ill. — The Foundation for Sarcoidosis Research (FSR) is honored to host its inaugural in-person training of FSR-GSCA Volunteer Patient Leaders from around the United States at Cleveland Clinic, the FSR Global Sarcoidosis Clinic Alliance (FSR-GSCA) Founding Member. This inaugural in-person training of FSR-GSCA Volunteer Patient Leaders has been...
SEATTLE, WA — A blood test intended for screening for colorectal cancer in people who are of average risk and not experiencing symptoms correctly detected colorectal cancer in 83% of people confirmed to have the disease, according to a study published March 14 in the New England Journal of Medicine....